Impact of bodyweight-based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma.

Takuji OkusakaMasatoshi KudoKenji IkedaMasafumi IkedaKiwamu OkitaMichiko SugawaraToshiyuki TamaiMin RenKenichi SaitoHiromitsu Kumada

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)

Comparison between patients in Study 202 and REFLECT demonstrates efficacy was maintained with improved safety in patients with lower bodyweights who received lenvatinib 8 mg/day in REFLECT versus patients who received lenvatinib 12 mg/day in Study 202.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors